Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

Abstract

Background: Avelumab, a human Ig-G1 monoclonal antibody targeting PD-L1 and approved in the USA for the treatment of metastatic Merkel cell carcinoma, has shown antitumour activity and an acceptable safety profile in patients with advanced solid tumours in a dose-escalation phase 1a trial. In this dose-expansion cohort of that trial, we assess avelumab treatment in a cohort of patients with advanced, platinum-treated non-small-cell lung cancer (NSCLC).

Methods: In this dose-expansion cohort of a multicentre, open-label, phase 1 study, patients with progressive or platinum-resistant metastatic or recurrent NSCLC were enrolled at 58 cancer treatment centres and academic hospitals in the USA. Eligible patients had confirmed stage IIIB or IV NSCLC with squamous or non-squamous histology, measurable disease by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1), tumour biopsy or archival sample for biomarker assessment, and Eastern Cooperative Oncology Group performance status 0 or 1, among other criteria. Patient selection was not based on PD-L1 expression or expression of other biomarkers, including EGFR or KRAS mutation or ALK translocation status. Patients received infusional avelumab monotherapy 10 mg/kg every 2 weeks until disease progression or toxicity. The primary objective was to assess safety and tolerability. This trial is registered with ClinicalTrials.gov, number NCT01772004; enrolment in this cohort is closed and the trial is ongoing.

Findings: Between Sept 10, 2013, and June 24, 2014, 184 patients were enrolled and initiated treatment with avelumab. Median follow-up duration was 8·8 months (IQR 7·2-11·9). The most common treatment-related adverse events of any grade were fatigue (46 [25%] of 184 patients), infusion-related reaction (38 [21%]), and nausea (23 [13%]). Grade 3 or worse treatment-related adverse events occurred in 23 (13%) of 184 patients; the most common (occurring in more than two patients) were infusion-related reaction (four [2%] patients) and increased lipase level (three [2%]). 16 (9%) of 184 patients had a serious adverse event related to treatment with avelumab, with infusion-related reaction (in four [2%] patients) and dyspnoea (in two [1%]) occurring in more than one patient. Serious adverse events irrespective of cause occurred in 80 (44%) of 184 patients. Those occurring in more than five patients (≥3%) were dyspnoea (ten patients [5%]), pneumonia (nine [5%]), and chronic obstructive pulmonary disease (six [3%]). Immune-related treatment-related events occurred in 22 patients (12%). Of 184 patients, 22 (12% [95% CI 8-18]) achieved a confirmed objective response, including one complete response and 21 partial responses. 70 (38%) had stable disease. Overall, 92 (50%) of 184 patients achieved disease control (they had a confirmed response or stable disease as their best overall response). One patient was initially thought to have died from grade 5 radiation pneumonitis during the study; however, this adverse event was subsequently regraded to grade 3 and the death was attributed to disease progression.

Interpretation: Avelumab showed an acceptable safety profile and antitumour activity in patients with progressive or treatment-resistant NSCLC, providing a rationale for further studies of avelumab in this disease setting.

Funding: Merck KGaA and Pfizer.

Conflict of interest statement

Conflict of Interest Statement:

D.J.L.W. reports research grant funding from Merck Serono. J.L. is an employee at PRA Health Sciences. J.L. reports institutional research funding from EMD Serono, relevant to the submitted work. J.L. reports institutional research funding from AstraZeneca, Genentech, and Clovis, outside the submitted work. W.J.E. reports participation in Speaker’s Bureau’s for Astellas and Novartis, outside the submitted work. H.J.G. and A.vH. are employees at Merck KGaA. A.vH. is a stockholder at Merck KGaA. K.C. is an employee at EMD Serono. J-M.C. was an employee of Merck KGaA. J-M.C. is an employee and stockholder at Angenus Bio. All other authors declare no competing interests.

Copyright © 2017 Elsevier Ltd. All rights reserved.

Figures

Figure 1

Trial profile

Figure 2. Percent change from baseline in target lesions over time

Spider plot of the change in sum of target lesions diameters from baseline over time for all evaluable patients (n=158), defined as those with baseline tumour assessments and at least one post-baseline assessment. Lines are color-coded based on BOR (confirmed and unconfirmed). Horizontal dashed lines represent RECIST v1.1 guideline for partial response (≥30% decrease in target lesion) and progressive disease (≥20% increase in target lesion).

Figure 3. Time to and duration of response in patients with complete response or partial response

Bars represent individual patients with partial response or complete response (confirmed and unconfirmed) and are color-coded based on PD-L1 status at the ≥1% tumour cell staining cut-off. Responses were ongoing in 20 patients at the time of data cut-off. Two PD-L1–, 20 PD-L1+, and four patients not evaluable for PD-L1 staining achieved a response. NE, not evaluable.

Figure 4

Kaplan-Meier estimates of progression-free survival (A) and overall survival (B) by PD-L1 expression status (≥1% tumour cell cut-off)